The Psychedelic News Feed
December 15 - 21, 2025
This is an archived version of our Psychedelic News Feed. Explore the live Feed and receive a weekly digest to your inbox by joining our free newsletter:
Learn more about and subscribe to our Pα+ program to receive lots, lots more. ∎
A Note from the Editor
This week, we published our last Bulletin of 2025, which featured interviews, policy and drug development updates, and a closer look at some recent research findings. Our attention now turns to planning for what is sure to be an eventful 2026, but not before we share our 2025 Year in Review.
This year, we’re doing things a little differently. While we will still share a couple of articles from our desk, a selection of global dispatches from guest authors, and Michael Haichin’s Interdisciplinary Annotated Psychedelic Research Bibliography, the core of our 2025 Year in Review coverage is in the form of a three-part narrated presentation that I have pulled together. In it, I share data and updates from around the world, as well as deep dives into specific topics, such as what I learned during a trip to D.C.
The first session, which looks back at 2025 and takes stock of where the field is today, with a primary focus on drug development and policy, will be shared early next week with our Pα+ subscribers. Join today to get access to the videos as they publish.
Below, you will find your Psychedelic News Feed, a one-stop digest for the latest coverage of psychedelics business, policy, research and beyond.
Josh Hardman
Founder & Editor
Psychedelic Bulletin 216 (Dec 17) ↗ Psychedelic Alpha
- Australia’s Department of Veterans’ Affairs Explains World-First Funding Model for Psychedelic-Assisted Psychotherapy
- New Mexico Targets December 2026 for Medical Psilocybin Launch
- Otsuka Publicly Signals Work on “Psychedelic-Inspired” CNS Compounds
- Psilocybin Promotes Growth of Existing Brain Tumours in Mice, Preprint Study Reports
- Interview: Radial Scores $50M, Eyes Interventional Psychiatry—and Psychedelics
- State of Texas Awards $50M to Ibogaine Study Consortium
- Interview: Fireside Project Unveils AI Chatbot Aimed at Training Psychedelic Practitioners
- Czech Medical Body Drafts Guidelines for Psilocybin Therapy, Targets 2026 Launch
- and more…
Psychedelic Research Shows Promise for Neurological Conditions (Dec 17) ↗ The Scientist
Treating Depression with Ketamine and Psilocybin (Dec 17) ↗ Understanding Animal Research
Psychedelics May Mess Up Brain Activity Scans (Dec 15) ↗ Futurity
Putting Ethics and Public Engagement at the Center of Psychedelics Exploration (Dec 16) ↗ BCSP
Psychedelics research in rodents has a behavior problem (Dec 19) ↗ The Transmitter
Cybin alters state to become Helus Pharma for Nasdaq trip (Dec 19) ↗ Fierce Pharma
The Lancet highlights the commitment of researchers at the Parc to integrate psychedelics with psychotherapy (Dec 17) ↗ SJD Parc Sanitari
The Psychedelic Scientist (Dec 16) ↗ Nautilus
This is an archived version of our Psychedelic News Feed. Explore the live Feed and receive a weekly digest to your inbox by joining our free newsletter:
Learn more about and subscribe to our Pα+ program to receive lots, lots more. ∎
